PCV100 Towards a paradigm shift in anticoagulation? too soon to conclude on cost-effectiveness of new anticoagulants  by Hagen, G. & Wisloff, T.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A289 
 
 
SAPIEN® transcatheter implantation therapy versus drug treatment with or 
without aortic balloon valvoplasty. The outcomes used were effectiveness (as 
measured by clinical outcomes chance of successful implantation procedure and 
survival) and safety. The results were expressed as the reason of incremental 
cost-effectiveness ratio (ICER) per years saved and years free from serious 
adverse events. Probabilistic sensitivity analysis was performed on the main 
parameters of the model. RESULTS: Compared with medical therapy with or 
without aortic balloon valvuloplasty, the employment of the SAPIEN® valve 
presents safety in the procedure, increased survival and compatible ICER – US$ 
40.000/life of year saved. CONCLUSIONS: The use of SAPIEN® transcatheter 
implantation results in improved survival and functional improvement in 
patients with low risk of serious adverse events, and demonstrates a cost-
effectiveness profile when compared to other technologies already incorporated 
by the Brazilian public health system.  
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OBJECTIVES: To evaluate the cost-effectiveness of apixaban compared to 
enoxaparin, rivaroxaban and dabigatran in venous thromboembolism prevention 
(VTEp) in patients undergoing elective total knee or hip replacement (TKR, THR) 
from the private payer’s perspective in Colombia. METHODS: An economic 
model, including both a decision tree component and a Markov model was 
created to compare apixaban 5mg/day, enoxaparin 40mg/day, dabigatran 
220mg/day and rivaroxaban 10mg/day. The decision tree considers potential 
VTE, bleeding, death events as well as no-events which occur over the short-
term and lends itself to model the prophylactic and post-prophylactic phases 
over the first 90 days post-surgery. Events that occur over the long term are 
modeled using a Markov structure, which provides the option to simulate events 
such as recurrent VTE and post-thrombotic syndrome. The model relies upon the 
results from a mixed treatment comparison study for key efficacy and safety 
inputs, information from published literature for unit cost and utility data, and 
Colombian cost and patterns of care study for resource use and event costs. 
Results are reported as cost per quality-adjusted life years gained (QALY’s) and 
life years gained (LYG) over a prophylaxis + five-year time horizon. A discount 
rate of 3.5% was used for both costs and outcomes. RESULTS: Results indicate 
that the use of apixaban is dominant compared to enoxaparin and dabigatran in 
the overall population for THR and TKR (less number of VTE events, total bleeds 
and deaths which generated higher number QALYs and lower overall costs). 
When compared to rivaroxaban the model results show similar long-term gains 
in QALY’s and LYG for apixaban, as well as similar costs -showing small savings 
for apixaban mainly due to lower bleeding costs. CONCLUSIONS: Apixaban is a 
cost-effective alternative in preventing VTE in patients undergoing THR or TKR 
in Colombian private setting.  
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OBJECTIVES: Most patients with myocardial infarction in Colombia are treated 
with streptokynase, despite tenecteplase being recognized as more effective. Our 
objective was to evaluate the cost-effectiveness and cost-utility of tenecteplase, 
compared with streptokinase, in the treatment of ST elevation myocardial 
infarction. METHODS: We designed a decision tree model, from the perspective 
of the Colombian health system. We calculated quality adjusted life years (QALY) 
gained (using data Tuft's registry), as well as cost per death, and cost per major 
outcome averted (death, stroke, severe heart failure). The costs were estimated 
in Colombian pesos for 2012 (Exchange rate 1US$=COP$1785) using national tariff 
manuals (Social Security 2001 with inflation adjustment) and resource use 
obtained from our local university hospital, validated by national expert panel. 
We performed a probabilistic and deterministic sensitivity analysis. RESULTS: 
The average total cost for a tenecteplase treated patient was US$1456. The cost 
per incremental QALY gained with tenecteplase was US$14,447; US$95,302 per 
death averted, and US$38,578 for major outcome averted. The average total cost 
for the treatment of acute phase of all myocardial infarctions for 2012 was 
estimated in US$728,000. Monte Carlo simulation acceptability curve showed 
that in 85% of the trials the result would be cost-effective, assuming a 
willingness to pay of up to three times the per capita gross domestic product 
(Colombia's per capita GDP is US$6723). If the cost of tenecteplase were lowered 
from US$2066 to US$389 the cost per QALY would reach the one per capita GDP 
threshold. CONCLUSIONS: Our results suggest that tenecteplase is cost effective 
if we accept the three-times per capita GDP threshold.  
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OBJECTIVES: The multi-centered, double-blind, randomized PLATO trial on 18,624 
patients from 43 countries has demonstrated that ticagrelor was superior in 
reducing the rates of cardiovascular mortality, myocardial infarction (MI), or stroke 
among patients with acute coronary syndrome (ACS) compared to clopidogrel but 
without a significant increase in major bleedings. This study aimed to evaluate the 
long-term cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus 
clopidogrel plus ASA in ACS patients in Hong Kong (HK) from a public hospital’s 
perspective. METHODS: A two-phase state-transition Markov model was developed 
to estimate the long-term economic and health outcomes measured as quality-
adjusted life years (QALYs). PLATO data were utilized to estimate patients’ resource 
use (incl. hospitalization bed days, investigations, interventions and blood products), 
rate of cardiovascular events (i.e. MI and stroke) and QALYs for the first year. 
Outcomes from the second year onwards were extrapolated using results from the 
first year. Direct health care costs were HK-specific and utility data were adopted 
from published literature. Time horizons were set at 1 year, 5 years and patients’ 
lifetime. All costs which were presented as 2012 figures and effectiveness were both 
discounted at 3% per annum. A series of one-way and multi-way sensitivity 
analyses were performed to test model robustness. RESULTS: Over a lifetime 
horizon, the use of ticagrelor led to improved clinical outcome with a discounted 
survival of 13.08 QALYs per patient in the ticagrelor treatment group compared to 
12.91 in the clopidogrel treatment group. Despite its higher daily cost, ticagrelor was 
predicted to significantly reduce resource utilization by HKD6,348 (USD814, 
1USD=7.8HKD) and stroke treatment cost by HKD45,226 (USD5,798) per patient 
which can be translated into a heavy public health care expenditure. 
CONCLUSIONS: The treatment of ACS patients with lifetime use of ticagrelor is 
considered cost-saving compared with clopidogrel from a public health care 
provider perspective in HK.  
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease 
characterized by uncoordinated atrial activation involving a rapid and irregular 
heartbeat. Its prevalence has been increasing worldwide. Antiarrhythmic drug 
therapy is a commonly-used treatment for paroxysmal AF, and catheter ablation 
has become an important treatment alternative. The purpose of this study was 
to assess the cost-effectiveness of catheter ablation compared to antiarrhythmic 
drug (AAD) therapy for the treatment of paroxysmal AF in Canada. METHODS: A 
simulation model was developed for a hypothetical cohort of 55-year-old 
patients with drug-refractory paroxysmal AF and a low stroke risk. The first year 
was modeled with a decision tree. Years 2 and beyond were modeled with a 
Markov simulation. The model treatment arms were catheter ablation and AAD 
mono-therapy. The model was created to assess costs and quality-adjusted life-
years over a lifetime horizon. Clinical efficacy of catheter ablation and AAD 
therapy were modeled based on the results of a recently-published randomized 
controlled trial (Wilber et al., 2010). Utilities and state transition probabilities 
were drawn from the published literature. Costs were specific to Canada. 
RESULTS: The incremental cost-effectiveness ratio for catheter ablation versus 
AAD therapy ranged from CAD$10,000 to a dominant strategy (cost less and is 
more effective) per quality-adjusted life-year. Over a lifetime horizon, the 
quality-adjusted life expectancy ranged from 11.25 to 11.75 years for catheter 
ablation compared to 10.75 to 11.25 years for AAD therapy. The results were 
robust in sensitivity analysis. Results were most sensitive to ablation costs, 
probability of successful ablation treatment, and probability of revision to AF. 
CONCLUSIONS: Catheter ablation appears to be cost-effective compared to AAD 
therapy among patients who had drug refractory paroxysmal AF in the Canadian 
population when using a cost-effectiveness threshold of CAD$50,000. Further 
research is necessary to understand the effect of newly approved OAC therapies. 
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OBJECTIVES: To evaluate the cost-effectiveness of new oral anticoagulants 
(apixaban, dabigatran and rivaroxaban) compared relative to each other and 
relative to warfarin for stroke prevention in patients with atrial fibrillation. 
METHODS: We developed a decision analytic model, designed as a probabilistic 
Markov model containing 200 different probability distributions. The model 
included eight health states; atrial fibrillation (AF), heart failure, moderate stroke 
sequela, severe stroke sequela, atrial fibrillation with previous AMI, atrial 
fibrillation with previous stroke, atrial fibrillation with major gastrointestinal 
bleeding and dead. Efficacy data was collected from a recently published report 
from the Canadian Health Technology Assessment Agency (CADTH). 
Epidemiological input data was gathered from registries. Data on Quality of Life 
were based on published EQ-5D data and costs were mainly based on national 
tariffs. The analysis was stratified according to risk of stroke as measured by 
CHA2DS2-VASc and risk of bleeding as measured by HAS-BLED. RESULTS: When 
the new drugs were compared relative to each other for medium risk patients, 
simulations indicated a 41% probability that apixaban is cost-effective, with 34% 
and 24% for dabigatran and rivaroxaban, respectively. For high risk patients, 
simulations indicated a 56% probability that dabigatran is cost-effective, with 
29% and 15% for apixaban and rivaroxaban, respectively. When comparing each 
of the new anticoagulants with the old (warfarin), analyses indicate a probability 
between 21% and 60% that warfarin is still cost-effective. In separate analyses, 
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we explored the influence of the price of apixaban. Conclusions are clearly, 
highly dependent on the assumed price of apixaban for this indication. 
CONCLUSIONS: The results indicate that there is great uncertainty regarding 
which treatment is the cost-effective alternative. Given current evidence, it may 
be too early to conclude that the new oral anticoagulants are cost-effective 
compared to warfarin.  
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OBJECTIVES: To estimate the cost-effectiveness of home telemonitoring (TM) or 
structured telephone support (STS) strategies versus usual care for adults recently 
discharged (within 28 days) after a heart failure (HF) exacerbation in England and 
Wales. METHODS: A Markov model was used to evaluate three interventions: 1) 
STS via human to machine (HM) interface; 2) STS via human to human (HH) 
contact; and 3) TM, against 4) usual care. Given heterogeneity in the interventions, 
cost-effectiveness analysis was performed using bottom up costing scenarios. Costs 
and quality adjusted life years (QALYs) over a 30-year horizon were estimated based 
on monthly probabilities of death and monthly risks of hospitalisations (HF-related 
complications or other causes) estimated from clinical effectiveness parameters 
computed using a network meta-analysis of randomised controlled trials. RESULTS: 
Base case monthly costs per patient were: £27 for usual care, £119 for STS HM, £179 
for STS HH and £175 for TM. TM was the most cost-effective strategy in the scenario 
using these base case costs. Compared with usual care, TM had an estimated 
incremental cost effectiveness ratio (ICER) of £9,552/QALY, whereas STS HH had an 
ICER of £63,240/QALY against TM. STS HM was dominated by usual care. 
Probabilistic sensitivity analysis (PSA) showed 44% chance of TM being cost-
effective with STS HH 36%, STS HM 18% and usual care 2%, respectively. Threshold 
analysis suggested that the monthly cost of TM has to be higher than £390 to have 
an ICER greater than £20,000/QALY against STS HH. Scenario analyses performed 
using higher costs of usual care, higher costs of STS HH and lower costs of TM do 
not substantially change the conclusions. CONCLUSIONS: Cost-effectiveness 
analyses suggest TM was an optimal strategy in most scenarios, but there is 
considerable uncertainty in relation to clear descriptions of the interventions and 
robust estimation of costs.  
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OBJECTIVES: A prescription synchronization and medication management 
program has been implemented in several community pharmacies to enhance 
medication adherence and provide greater efficiency in the pharmacy. The 
objectives of this analysis were to examine the impact of the program on chronic 
medication adherence and health care costs. METHODS: A cross-sectional 
analysis using Mississippi Medicaid claims from 2008-2011 was undertaken. 
Claims for three drug-classes including statins, antihypertensives, and oral 
hypoglycemics were extracted from a pharmacy that implemented the program 
and the other pharmacies serving patients in the same geographic area. First, a 
retrospective matched cohort analysis was undertaken to compare medication 
adherence measured as the proportion of days covered (PDC) and medical costs 
3, 6, 9, and 12 months from the index date. Patients in the two groups were 
matched on age, gender, and race using a greedy-match algorithm. Second, a 
pre-post analysis comparing medication adherence and costs was conducted 
before and after the enrolling in the target pharmacy program. RESULTS: In the 
matched analysis, the average PDC three months (90.87% vs. 84.27%; p=0.002) 
and six months (87.91% vs. 81.86%; p=0.01) after the index date was significantly 
higher in the target pharmacy group than in the other group. Average medical 
costs 3 months ($2,326.52 vs. $1,802.41; p<0.0001) and 12 months ($7,505.36 vs. 
$7,446.77; p=0.04) after the index date were significantly higher in the other 
pharmacy group than in the target pharmacy group. In the pre-post analysis, the 
average PDC before enrolling in the target pharmacy service was significantly 
lower than after enrollment (70.3% vs. 84.2%; p<0.0001). In addition, average 
medical costs per patient per month significantly reduced from $584 in the pre-
period to $420 in the post-period (p<0.0001). CONCLUSIONS: The new service 
was not only associated with improved medication adherence, but also with 
decreased medical expenditures among chronic patients.  
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MEDICATION COMPLIANCE STATUS IN PATIENTS WITH HYPERTENSION AND 
ITS ASSOCIATED FACTORS IN URBAN CHINA  
Dong CH1, He MM2, Fan CS3, Wang D4 
1Ministry of Human Resources and Social Security, China, Beijing, China, 2Beijing University of 
Chinese Medicine, Beijing, China, 3Peking University Health Science Center, Beijing, China, 
4Beijing Novartis Pharma Co., Ltd., Beijing, China  
OBJECTIVES: To understand current medication compliance status of 
hypertension and its associated factors in urban China. METHODS: A 
community-based hypertension health survey was conducted in 2 cities of China 
(Beijing and Hangzhou) from Nov 2011 to Aug 2012. 10 community health service 
centers in each city were selected through cluster sampling. Hypertension 
patients who registered in the study sites were recruited by field investigators 
using standardized questionnaires. Patient data were collected including socio-
demographic characteristics, disease profile, treatment pattern, and health 
education awareness. Medication compliance was assessed by Morisky score. 
Self-reported health utility and social support scale instruments were also 
employed. Logistic regression and multivariate analysis were used to explore the 
associated factors affecting medication compliance in hypertension. RESULTS: In 
total, 1006 patients with hypertension were included, with average age of 
65.26±11.27 years old. 40.85% were male. The average duration of hypertension is 
12.35±10.27 years. 761 patients (75.65%) managed to control blood pressure under 
140/90 mmHG based on last blood pressure detected. 89.76% of the study 
subjects had less than 3 complications. Results show that 67.1% subjects 
achieved high level of compliance, 25.94% were moderate compliant, and 6.96% 
were non-compliant. The main influential factors of non-compliance were 
forgetting to take medicine (57.1%) and self-awareness of disease remission 
(32.6%). Multivariate analysis showed that compliance was positively associated 
with age, disease duration and social support, while negatively associated with 
existence of hypertension complications. Household income and reimbursement 
status were not major factors affecting medication compliance. Patients with 
high level of compliance also reported to have better health utility scores. 
CONCLUSIONS: The compliance status in hypertension in urban China is 
relatively poor. Strengthening family support and implementing effective health 
are important to improve medication compliance in hypertension, which may 
lead to improved patient reported outcomes.  
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IDENTIFYING PRIMARY NON-ADHERENCE RATES OF HMG-COA REDUCTASE 
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OBJECTIVES: Primary non-adherence occurs when a patient does not fill the 
prescription for a newly initiated medication. Contrary to the commonly 
researched concept of medication non-adherence (ie, secondary non-adherence), 
failure to start a new medication is less studied and can potentially pose a 
similar challenge to disease management. Our objective was to observe the 
primary non-adherence rate of newly initiated statins within 6 and 21 days of an 
electronic prescription. This study also explored differences in characteristics 
between primary adherent and non-adherent groups. METHODS: This was a 
retrospective observational study, using electronic prescriptions and pharmacy 
claims and sales records from Scott & White Health Plan (Temple, Texas, USA). 
Adult patients (n=2879) were included in the study if they had no prior exposure 
to any anti-hyperlipidemic drugs and received their first statin prescription from 
September 2009-May 2012. Outcomes measured included primary non-
adherence rates within 6 and 21 days after a new statin prescription was written. 
Characteristics (eg, age, gender, race, Charlson Comorbidity Index, prescriber 
type) were compared between adherent and non-adherent groups using 
descriptive statistics and logistic regression. RESULTS: The 6- and 21-day 
primary non-adherence rates were 29.2% and 21.7%, respectively. Logistic 
regression of 6-day primary adherence revealed that women were less likely to 
be non-adherent than men (OR: 0.815; 95% CI: 0.693–0.960), and African 
Americans were more likely than whites to be non-adherent (OR: 1.486; 95% CI: 
1.107–1.995). Patients were less likely to fill prescriptions written by allied health 
professionals than primary care providers (OR: 0.673; 95% CI: 0.465–0.974). 
CONCLUSIONS: This is one of the few studies to investigate primary non-
adherence in a real-world setting, and the results may be helpful in solving 
another piece of the overall non-adherence puzzle. Exploratory analysis 
indicated that male gender and African American race were predictors of 
primary non-adherence to statins.  
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OBJECTIVES: Despite the rising prevalence of hypertension and the availability 
of evidence-based guidelines for effective treatments, blood pressure (BP) control 
rates remain low. The purpose of this study was to evaluate the effect of 
telephone counseling intervention on blood pressure control. METHODS: Adults 
with hypertension attending the Centre for Diagnosis and Therapy of Arterial 
Hypertension of Cardarelli Hospital, Naples, Italy were randomly allocated to 
receive a pharmacist/counselor-administered counseling intervention (group I) 
or usual care (group C). Group I patients received the counseling intervention bi-
monthly for two years via telephone; the goal of the intervention was to promote 
medication adherence and improve hypertension-related health behaviors. The 
telephone intervention focused on perceived risk of hypertension and 
knowledge, memory, medical and social support, patients' relationship with 
their health care provider, adverse effects of medication therapy, weight 
management, exercise, diet, smoking, and alcohol use. BP values were registered 
at baseline, after one year and at the end of the investigation for both groups. 
Medication adherence (Belief Medicine Questionnaire, BMQ) was also assessed. 
Analysis was performed using SPSS version 19.0 RESULTS: Group I consisted of 
84 patients. A comparable sample was assigned to group C (n=80). The average 
phone call lasted 18 minutes (range 7 to 45 minutes). After two years there was a 
significant reduction of BP values for group I (t=0: Systolic=146.8±2.3 
Diastolic=90.2±4.2, t=24 months Systolic=138.4±4.6 Diastolic=86.9±3.8) (P<0.001). 
From baseline to two years, BMQ analysis showed an adherence improvement in 
group I (t=0 Necessity Score=15.6±3.5, concern Score=14.9±2.9, t=24 Necessity 
Score=22.4±2.4 and Concern Score=10±2.2). Group C did not show any 
statistically significant results. CONCLUSIONS: These findings suggest that 
